RESEARCH · GLOW BLEND · HEART AND CARDIAC INJURY MODELS
GLOW BLEND Components in Heart Research: Thymosin Beta-4 After Infarction, BPC-157 Arrhythmia Models and the Gaps
PurixLab’s GLOW BLEND 70mg is a research vial combining BPC-157, TB-500 and GHK-Cu. Our earlier articles cover the blend’s components and angiogenesis models, and a separate article on ischaemia-reperfusion models touched on the heart. This article looks at cardiac research in more detail: thymosin beta-4 (Tβ4) in myocardial infarction, the studies that questioned it, the Tβ4 fragment Ac-SDKP, BPC-157 studies of infarction and arrhythmia in rats, and the very limited GHK-Cu data. These are findings on the individual molecules; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.
Thymosin beta-4 after myocardial infarction
The founding study. In 2004, Bock-Marquette and colleagues showed that Tβ4, a G-actin sequestering peptide, promoted migration of myocardial and endothelial cells in the embryonic heart and survival of cultured cardiomyocytes. It formed a complex with PINCH and integrin-linked kinase (ILK) that activated the survival kinase Akt. After coronary artery ligation in mice, Tβ4 increased ILK and Akt activity, enhanced early myocyte survival and improved cardiac function [1].
The epicardium. Smart and colleagues then reported that Tβ4 was essential for coronary vessel development in mice and stimulated outgrowth from quiescent adult epicardial explants, which differentiated into fibroblasts, smooth muscle cells and endothelial cells [2]. In 2011 the same group reported that priming with Tβ4 before infarction reactivated the embryonic epicardial gene Wt1 and mobilised a progenitor population that gave rise to new cardiomyocytes integrating with resident muscle [3].
A large-animal model. In pigs (n = 9 per group) with 60 minutes of coronary occlusion, embryonic endothelial progenitor cells reduced infarct size from 54% to 38% of the area at risk, an effect abolished by Tβ4 knockdown in the cells. Delivering Tβ4 itself into the coronary vein mimicked the cells, with an infarct size of 37% and improved segmental shortening at 24 hours [4].
Follow-up mechanisms. Later work pointed to several routes. An oxidised form, Tβ4-sulfoxide, reduced inflammatory macrophages at wound sites in zebrafish and promoted healing with less scarring after cardiac injury in mice [5]. A study of 17 domain combinations of Tβ4 concluded that the C-terminal tetrapeptide AGES was responsible for most of the benefit in post-ischaemic heart function in mice and pigs [6]. A 2025 miRNA study linked Tβ4 to lower ROCK1 and less fibroblast-to-myofibroblast transformation after permanent ligation in mice [7].
The studies that did not agree
Tβ4 cardiac biology is contested. Global and cardiac-specific Tβ4 knockout mice were born at Mendelian ratios with normal hearts and vessels, normal adult cardiac function and normal epicardial markers, which led the authors to call Tβ4 dispensable for heart development and adult function [8]. The original group later reported a subtler phenotype in knockout mice: shorter sarcomeres, abnormal titin splicing and, by MRI, lower stroke volume and limited contractile reserve [9]. An independent attempt to reproduce progenitor activation in an Islet-1 reporter line found only a single Islet-1-positive cell outside expected regions in 8 Tβ4-treated infarcted hearts, and concluded there was no evidence of Islet-1 reactivation [10]. In a pig model of global ischaemia-reperfusion during cardiopulmonary bypass, Tβ4 given before and after ischaemia did not reduce cell death or change cardiac function [11]. Results seem to depend on the model, the timing and the laboratory.
Ac-SDKP, a Tβ4 fragment
Tβ4 is cleaved to the tetrapeptide N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP). Tβ4 knockdown in the heart reduced Ac-SDKP, and Ac-SDKP enhanced endothelial differentiation of adult epicardium-derived cells, though it could not rescue Tβ4-deficient hearts [2]. In rats with heart failure after infarction, Ac-SDKP reduced collagen, macrophage infiltration and TGF-beta-positive cells in non-infarcted myocardium in both prevention and reversal designs. It did not improve cardiac function, and it depressed systolic function in the prevention study [12]. Less fibrosis did not translate into a better-working heart.
Human data exist only for full-length Tβ4
A first-in-human phase I study of recombinant human Tβ4 enrolled 54 healthy volunteers in single-ascending cohorts and 30 in multiple-administration cohorts; adverse events were mild to moderate, with no serious adverse events [13]. A 2025 report paired mouse ischaemia-reperfusion experiments with a randomised, placebo-controlled, double-blind trial in 96 patients with ST-elevation myocardial infarction after primary PCI. Infarcted areas were smaller with Tβ4 in the subgroup treated within 8 h of PCI (n = 43), but the overall difference across all 96 patients was not significant [14].
BPC-157 in rat heart models
BPC-157 cardiac studies come almost entirely from one Zagreb group, summarised in its own 2022 review [15].
- Isoprenaline infarction. In rats given isoprenaline, BPC-157 lowered CK, CK-MB, LDH and cardiac troponin T, attenuated gross and histological damage, prevented ischaemic ST-T changes on ECG and preserved systolic left ventricular function on echocardiography [16].
- Digitalis arrhythmias. In methyldigoxin toxicity, BPC-157 reduced ventricular premature beats, ventricular tachycardia and AV block; the NOS inhibitor L-NAME worsened the arrhythmias [17].
- Hyperkalaemia. After potassium chloride overdose, BPC-157 given before or after the challenge restored sinus rhythm, and in HEK293 cells it affected potassium conductance under hyperkalaemic conditions [18]. It also counteracted hyperkalaemia and arrhythmias after succinylcholine [19].
- QTc prolongation. BPC-157 counteracted QTc prolongation induced by haloperidol, clozapine, olanzapine, quetiapine and other neuroleptics or prokinetics [20].
- Right heart. In monocrotaline-induced pulmonary hypertension, early and delayed BPC-157 regimens counteracted right ventricular pressure rise, right heart hypertrophy and ECG changes [21].
The effects reported are large and consistent, but none has been reproduced by an independent laboratory, mechanisms rest mainly on L-NAME and L-arginine interaction experiments, and we found no human cardiac study of BPC-157.
GHK-Cu: almost no cardiac data
For GHK-Cu we found no mammalian heart study on PubMed. The closest is a zebrafish study in which recombinant GHK bound copper 1:1 and protected larvae against bradycardia and irregular heartbeat caused by waterborne copper; stroke volume, ejection fraction and fractional shortening were not significantly altered [22]. That is a copper-chelation toxicity model, not cardiac injury.
What is unknown about the combination
- No combination study. We found no cardiac study testing BPC-157, a Tβ4 fragment and GHK-Cu together.
- Fragment versus full-length. The cardiac Tβ4 literature uses the 43-amino-acid protein or its sulfoxide, AGES or Ac-SDKP, not TB-500 [6,12].
- Replication. Key Tβ4 findings were contradicted, and BPC-157 data come from one group [8,10,11,15].
- Endpoints. Many studies end at 24 hours or a few weeks, and the only clinical efficacy trial missed its overall comparison [4,14].
GLOW BLEND 70mg at PurixLab
GLOW BLEND 70mg: a labelled lyophilized research vial combining BPC-157, TB-500 and GHK-Cu (10mg + 10mg + 50mg, 70mg total per vial), C$136 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/glow-blend-70mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-72. PubMed 15565145 · doi:10.1038/nature03000
- Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-82. PubMed 17108969 · doi:10.1038/nature05383
- Smart N, Bollini S, Dubé KN, et al. De novo cardiomyocytes from within the activated adult heart after injury. Nature. 2011;474(7353):640-4. PubMed 21654746 · PMC3696525 · doi:10.1038/nature10188
- Hinkel R, El-Aouni C, Olson T, et al. Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection. Circulation. 2008;117(17):2232-40. PubMed 18427126 · PMC2672916 · doi:10.1161/CIRCULATIONAHA.107.758904
- Evans MA, Smart N, Dubé KN, et al. Thymosin β4-sulfoxide attenuates inflammatory cell infiltration and promotes cardiac wound healing. Nat Commun. 2013;4:2081. PubMed 23820300 · PMC3797509 · doi:10.1038/ncomms3081
- Hinkel R, Ball HL, DiMaio JM, et al. C-terminal variable AGES domain of Thymosin β4: the molecule's primary contribution in support of post-ischemic cardiac function and repair. J Mol Cell Cardiol. 2015;87:113-25. PubMed 26255251 · doi:10.1016/j.yjmcc.2015.07.004
- Maar K, Thatcher JE, Karpov E, et al. Thymosin Beta-4 Modulates Cardiac Remodeling by Regulating ROCK1 Expression in Adult Mammals. Int J Mol Sci. 2025;26(9):4131. PubMed 40362372 · PMC12072014 · doi:10.3390/ijms26094131
- Banerjee I, Zhang J, Moore-Morris T, et al. Thymosin beta 4 is dispensable for murine cardiac development and function. Circ Res. 2012;110(3):456-64. PubMed 22158707 · PMC3739283 · doi:10.1161/CIRCRESAHA.111.258616
- Smart N, Riegler J, Turtle CW, et al. Aberrant developmental titin splicing and dysregulated sarcomere length in Thymosin β4 knockout mice. J Mol Cell Cardiol. 2017;102:94-107. PubMed 27914791 · PMC5319848 · doi:10.1016/j.yjmcc.2016.10.010
- Weinberger F, Nicol P, Starbatty J, et al. No effect of thymosin beta-4 on the expression of the transcription factor Islet-1 in the adult murine heart. Pharmacol Res Perspect. 2018;6(3):e00407. PubMed 29864245 · PMC5986028 · doi:10.1002/prp2.407
- Stark CK, Tarkia M, Kentala R, et al. Systemic Dosing of Thymosin Beta 4 before and after Ischemia Does Not Attenuate Global Myocardial Ischemia-Reperfusion Injury in Pigs. Front Pharmacol. 2016;7:115. PubMed 27199757 · PMC4853610 · doi:10.3389/fphar.2016.00115
- Yang F, Yang XP, Liu YH, et al. Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension. 2004;43(2):229-36. PubMed 14691195 · PMC3259854 · doi:10.1161/01.HYP.0000107777.91185.89
- Wang X, Liu L, Qi L, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228. PubMed 34346165 · PMC8419156 · doi:10.1111/jcmm.16693
- Zhang Y, Dong Q, Bian X, et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res. 2025;121(17):2747-2758. PubMed 41229390 · doi:10.1093/cvr/cvaf223
- Sikiric P, Udovicic M, Barisic I, et al. Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy in the Heart Disturbances, Myocardial Infarction, Heart Failure, Pulmonary Hypertension, Arrhythmias, and Thrombosis Presentation. Biomedicines. 2022;10(11):2696. PubMed 36359218 · PMC9687817 · doi:10.3390/biomedicines10112696
- Barisic I, Balenovic D, Udovicic M, et al. Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats. Biomedicines. 2022;10(2):265. PubMed 35203478 · PMC8869603 · doi:10.3390/biomedicines10020265
- Balenovic D, Bencic ML, Udovicic M, et al. Inhibition of methyldigoxin-induced arrhythmias by pentadecapeptide BPC 157: a relation with NO-system. Regul Pept. 2009;156(1-3):83-9. PubMed 19465062 · doi:10.1016/j.regpep.2009.05.008
- Barisic I, Balenovic D, Klicek R, et al. Mortal hyperkalemia disturbances in rats are NO-system related. The life saving effect of pentadecapeptide BPC 157. Regul Pept. 2013;181:50-66. PubMed 23327997 · doi:10.1016/j.regpep.2012.12.007
- Stambolija V, Stambolija TP, Holjevac JK, et al. BPC 157: The counteraction of succinylcholine, hyperkalemia, and arrhythmias. Eur J Pharmacol. 2016;781:83-91. PubMed 27060013 · doi:10.1016/j.ejphar.2016.04.004
- Strinic D, Belosic Halle Z, Luetic K, et al. BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats. Life Sci. 2017;186:66-79. PubMed 28797793 · doi:10.1016/j.lfs.2017.08.006
- Udovicic M, Sever M, Kavur L, et al. Stable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal. Biomedicines. 2021;9(7):822. PubMed 34356886 · PMC8301325 · doi:10.3390/biomedicines9070822
- Hsiao CD, Wu HH, Malhotra N, et al. Expression and Purification of Recombinant GHK Tripeptides Are Able to Protect against Acute Cardiotoxicity from Exposure to Waterborne-Copper in Zebrafish. Biomolecules. 2020;10(9):1202. PubMed 32825031 · PMC7564529 · doi:10.3390/biom10091202